{"schema_version":"secwatch.filing_event.v1","accession":"0001964738-25-000062","form_type":"8-K","ticker":"SOLV","cik":"0001964738","company_name":"Solventum Corp","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.712021+00:00","generated_at":"2026-05-17T18:28:19.042146+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Solventum Q2 sales up 3.9% to $2.2B; raises FY organic growth & EPS guidance","bullets":["GAAP diluted EPS $0.51; adjusted diluted EPS $1.69 (+8.3% YoY).","Organic sales +2.8%; all segments positive, led by MedSurg and HIS.","Adjusted operating margin expanded 120 bps to 21.9%.","FY 2025 organic sales guidance raised to +2.0%-3.0%; EPS raised to $5.80-$5.95.","Operating cash flow $169M; free cash flow $59M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001964738-25-000062","json":"https://secwatch.observer/filing/0001964738-25-000062.json","markdown":"https://secwatch.observer/filing/0001964738-25-000062.md","text":"https://secwatch.observer/filing/0001964738-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964738/000196473825000062/0001964738-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964738/000196473825000062/solv-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:28:19.042146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}